Melbourne, Australia, 29 June 2022: Certa Therapeutics, a biotechnology company focused on improving lives by developing innovative precision treatments for inflammatory and fibrotic diseases.
Today the world’s scleroderma community comes together to recognise World Scleroderma Day. Certa Therapeutics joins the community in highlighting the need to increase awareness of scleroderma and to advocate for those affected by this life-threatening disease.
“Certa Therapeutics are on a mission to increase awareness of scleroderma and to advocate for those affected by this life-threatening and debilitating disease,” said Professor Darren Kelly, Chief Executive Officer of Certa Therapeutics.
Scleroderma, also known as systemic sclerosis (SSc), is a rare, chronic, often progressive autoimmune disease, causing inflammation and fibrosis (scarring/hardening) of the skin and other organs.
At present there is no cure for scleroderma and current approved therapies are largely ineffective and can have significant side-effects. Part of the limitations for therapeutic options in scleroderma is that no current drugs directly act on the fibrosis itself, a key feature of this progressive disease. Certa Therapeutics recognises the importance of developing a new innovative treatment that is better suited to patient needs.
Certa Therapeutics lead anti-fibrotic drug candidate, FT011 has demonstrated efficacy in numerous pre-clinical disease models, as well as an excellent safety profile in a phase I clinical trial.. Certa Therapeutics is now conducting a Phase 2 study of the FT011 in diffuse SSc.
In addition to the development of FT011 as a potential treatment for SSc, Certa Therapeutics is using genetic analysis to identify the most suitable patients for treatment.
“We are pleased to provide some hope to patients with SSc on this year’s World Scleroderma Day. We understand the importance of developing these new therapies to provide relief to those in need. The team here at Certa are focused on advancing the candidate therapy FT011 which has the potential to improve patient lives,” said Professor Kelly, Chief Executive Officer of Certa Therapeutics.